610794-15-5 Usage
General Description
1H-Indole, 4-bromo-5-methyl- is a chemical compound with the molecular formula C9H8BrN. It is a derivative of indole, a heterocyclic aromatic organic compound. This chemical is a yellowish-brown solid at room temperature, with a distinct odor. It is commonly used in the synthesis of pharmaceutical drugs, agrochemicals, and dyes. It is also being studied for its potential biological and pharmacological activities, including its potential as an anti-cancer agent and central nervous system depressant. However, due to its potentially harmful effects, it should be handled and used with caution and under proper safety precautions.
Check Digit Verification of cas no
The CAS Registry Mumber 610794-15-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,1,0,7,9 and 4 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 610794-15:
(8*6)+(7*1)+(6*0)+(5*7)+(4*9)+(3*4)+(2*1)+(1*5)=145
145 % 10 = 5
So 610794-15-5 is a valid CAS Registry Number.
610794-15-5Relevant articles and documents
QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY
-
Paragraph 0233, (2016/02/29)
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
SERINE/THREONINE PAK1 INHIBITORS
-
Page/Page column 170, (2013/03/26)
Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS
-
Page/Page column 61-62, (2008/12/07)
The present application, describes organic compounds of formula I that are useful for the treatment, prevention and/or amelioration of cyclin dependent limase mediated diseases. (I)